Market closedNon-fractionalADR
PureTech Health/PRTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About PureTech Health
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
Ticker
PRTC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Boston, United States
Employees
111
Website
puretechhealth.com
PureTech Health Metrics
BasicAdvanced
$806M
Market cap
-
P/E ratio
-$1.66
EPS
1.25
Beta
-
Dividend rate
Price and volume
Market cap
$806M
Beta
1.25
52-week high
$34.00
52-week low
$17.08
Average daily volume
0.04
Financial strength
Current ratio
7.309
Long term debt to equity
3.893
Total debt to equity
4.979
Interest coverage (TTM)
-34.79%
Management effectiveness
Return on assets (TTM)
-5.16%
Return on equity (TTM)
-8.58%
Return on investment (TTM)
-5.90%
Valuation
Price to revenue (TTM)
68.673
Price to tangible book (TTM)
1.572
Growth
Revenue change (TTM)
-36.83%
Earnings per share change (TTM)
-255.18%
3-year revenue growth (CAGR)
16.78%
What the Analysts think about PureTech Health
Analyst Ratings
Majority rating from 1 analysts.
PureTech Health Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
$3.1M
-63.53%
Net income
-$25M
13.64%
Profit margin
-806.45%
211.59%
PureTech Health Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 22
Q4 22
Q2 23
Q4 23
Actual
-$1.00
-$0.80
-$3.18
-$3.20
Expected
-$2.75
$0.34
-
-
Surprise
-63.57%
-335.29%
-
-
PureTech Health News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PureTech Health stock?
PureTech Health (PRTC) has a market cap of $806M as of July 27, 2024.
What is the P/E ratio for PureTech Health stock?
The price to earnings (P/E) ratio for PureTech Health (PRTC) stock is 0 as of July 27, 2024.
Does PureTech Health stock pay dividends?
No, PureTech Health (PRTC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next PureTech Health dividend payment date?
PureTech Health (PRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for PureTech Health?
PureTech Health (PRTC) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell PureTech Health stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.